Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)

NCT05934864 ·Status: RECRUITING

CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma

NCT01806337 ·Status: COMPLETED ·Phase: PHASE2

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

NCT04134325 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1

Minimal Residual Disease in Peripheral T-cell Lymphoma

NCT03297697 ·Status: COMPLETED

Study of Prognostic Factors in Adult Lymphoblastic Lymphoma

NCT03571997 ·Status: UNKNOWN

Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma

NCT07300514 ·Status: RECRUITING ·Phase: PHASE3

Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP

NCT00725231 ·Status: UNKNOWN ·Phase: PHASE3

Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

NCT05557903 ·Status: UNKNOWN ·Phase: PHASE1

Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma

NCT06761274 ·Status: RECRUITING ·Phase: NA

Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma

NCT01679860 ·Status: COMPLETED ·Phase: PHASE2

Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT

NCT01144754 ·Status: TERMINATED

Registry Study for Talimogene Laherparepvec

NCT02173171 ·Status: COMPLETED

Study on Plasmablastic Lymphoma Patients

NCT06781359 ·Status: RECRUITING

TREatment of degeNerative and Neoplastic Diseases With Rituximab

NCT01277172 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)

NCT06347653 ·Status: RECRUITING ·Phase: PHASE2

Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma

NCT05182957 ·Status: RECRUITING ·Phase: PHASE2

Study of the Pronostic Impact of Immunohistochemical, Histological and Radiological Factors in Patients With Primary Central Nervous System Lymphoma.

NCT05347511 ·Status: UNKNOWN

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

NCT05821192 ·Status: UNKNOWN ·Phase: NA

Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.

NCT03964480 ·Status: RECRUITING

A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma

NCT06963632 ·Status: NOT_YET_RECRUITING

Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas

NCT06089941 ·Status: ACTIVE_NOT_RECRUITING

Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma

NCT00008021 ·Status: UNKNOWN ·Phase: PHASE1

CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

NCT04021082 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3

Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma

NCT06744075 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight

NCT07046182 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4